Ontology highlight
ABSTRACT:
SUBMITTER: Coates LC
PROVIDER: S-EPMC6286532 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature
Coates L C LC Gladman D D DD Nash P P FitzGerald O O Kavanaugh A A Kvien T K TK Gossec L L Strand V V Rasouliyan L L Pricop L L Ding K K Jugl S M SM Gaillez C C
Arthritis research & therapy 20181207 1
<h4>Background</h4>Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). This post hoc analysis assessed the ability of secukinumab to achieve Psoriatic Arthritis Disease Activity Score (PASDAS)-based remission or low disease activity (LDA) through 2 years among patients with PsA in the FUTURE 2 study.<h4>Methods</h4>PASDAS (cut-off scores: remission ≤ 1.9; LDA > 1.9 and < 3.2; Moderate Disease ...[more]